{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:26:06Z","timestamp":1792218366556,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Beijing life Qasis Public Service Center","award":["cphcf-2022-024"],"award-info":[{"award-number":["cphcf-2022-024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The relationship between antibiotic treatment and immunotherapy efficacy is complex.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study was a single-center study. History of antibiotic use in gastric cancer (GC) patients within 1 or 3 months prior to immunotherapy was collected. Patients were categorized into 3 groups according to whether they had used antibiotics prior to immunotherapy: none, prophylactic use, and infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 252 GC patients received immunotherapy, of which 38.5% (97\/252) received antibiotic treatment within 1 month before immunotherapy (prophylactic use in 72.2% of patients) and 48.8% (123\/252) received antibiotic treatment within 3 months before immunotherapy (prophylactic use in 74.8% of patients). The prophylactic use of antibiotic within 1 month prior to immunotherapy significantly improved overall survival (OS) compared with patients who received anti-infective therapy and had no history of antibiotic use (prophylactic vs infection: OS, 22.6 vs 9.7 m, HR, 0.53, 95% CI, 0.27-1.07; prophylactic vs none: OS, 22.6 vs 14.7 m, HR, 0.57; 95% CI, 0.39-0.83). The use of antibiotics in infected patients did not increase the risk of death in patients compared with those who did not use antibiotics. Prophylactic antibiotic use within 1 month before immunotherapy is an independent prognostic factor for OS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Prophylactic use of antibiotics is associated with better prognosis in GC patients receiving immunotherapy. Therefore, there is no necessity to delay the use of immune checkpoint inhibitors in this group of patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae362","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T21:47:05Z","timestamp":1741124825000},"source":"Crossref","is-referenced-by-count":8,"title":["Prophylactic antibiotic use is associated with better clinical outcomes in gastric cancer patients receiving immunotherapy"],"prefix":"10.1093","volume":"30","author":[{"given":"Fangyuan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong, University of Science and Technology , Wuhan 430000, Hubei ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Ding","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University , Lanzhou, 730000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong, University of Science and Technology , Wuhan 430000, Hubei ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong, University of Science and Technology , Wuhan 430000, Hubei ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengbo","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong, University of Science and Technology , Wuhan 430000, Hubei ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong, University of Science and Technology , Wuhan 430000, Hubei ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong, University of Science and Technology , Wuhan 430000, Hubei ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong, University of Science and Technology , Wuhan 430000, Hubei ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2480-6332","authenticated-orcid":false,"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong, University of Science and Technology , Wuhan 430000, Hubei ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"2025030422480139500_CIT0001","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"2025030422480139500_CIT0002","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"2025030422480139500_CIT0003","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"2025030422480139500_CIT0004","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1158\/2159-8290.CD-20-1312","article-title":"Paradigms on immunotherapy combinations with chemotherapy","volume":"11","author":"Salas-Benito","year":"2021","journal-title":"Cancer Discov"},{"key":"2025030422480139500_CIT0005","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"2025030422480139500_CIT0006","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"2025030422480139500_CIT0007","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025030422480139500_CIT0008","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41568-023-00594-2","article-title":"Bacteria in cancer initiation, promotion and progression","volume":"23","author":"El Tekle","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"2025030422480139500_CIT0009","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aah5043","article-title":"Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine","volume":"357","author":"Geller","year":"2017","journal-title":"Science"},{"key":"2025030422480139500_CIT0010","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41579-023-00933-y","article-title":"Antibiotic perturbations to the gut microbiome","volume":"21","author":"Fishbein","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2025030422480139500_CIT0011","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"2025030422480139500_CIT0012","doi-asserted-by":"publisher","first-page":"772532","DOI":"10.3389\/fimmu.2021.772532","article-title":"Adjunctive Probiotic Lactobacillus rhamnosus Probio-M9 administration enhances the effect of Anti-PD-1 antitumor therapy via restoring antibiotic-disrupted gut microbiota","volume":"12","author":"Gao","year":"2021","journal-title":"Front Immunol"},{"key":"2025030422480139500_CIT0013","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11684-022-0927-0","article-title":"Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy","volume":"16","author":"Li","year":"2022","journal-title":"Front Med"},{"key":"2025030422480139500_CIT0014","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/08923973.2022.2145966","article-title":"Effect of concomitant antibiotics use on patient outcomes and adverse effects in patients treated with ICIs","volume":"45","author":"Yu","year":"2023","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2025030422480139500_CIT0015","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.lungcan.2019.01.017","article-title":"Antibiotics are associated with attenuated efficacy of anti-PD-1\/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer","volume":"130","author":"Zhao","year":"2019","journal-title":"Lung Cancer"},{"key":"2025030422480139500_CIT0016","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.cllc.2023.01.004","article-title":"Antibiotic treatment is an independent poor risk factor in NSCLC but not in melanoma patients who had received anti-PD-1\/L1 monotherapy","volume":"24","author":"Vihinen","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"2025030422480139500_CIT0017","doi-asserted-by":"publisher","first-page":"e1568812","DOI":"10.1080\/2162402X.2019.1568812","article-title":"Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors","volume":"8","author":"Elkrief","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025030422480139500_CIT0018","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ejca.2021.08.036","article-title":"Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events","volume":"157","author":"Kostine","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025030422480139500_CIT0019","doi-asserted-by":"publisher","first-page":"e003779","DOI":"10.1136\/jitc-2021-003779","article-title":"Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy","volume":"10","author":"Jing","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"2025030422480139500_CIT0020","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/jnci\/djac019","article-title":"The association between antibiotic use and outcome among metastatic melanoma patients receiving immunotherapy","volume":"114","author":"Poizeau","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"2025030422480139500_CIT0021","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1158\/1538-7445.AM2021-485","article-title":"Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: Evidence from an observational study","volume":"81","author":"Fessas","year":"2021","journal-title":"AACR"},{"key":"2025030422480139500_CIT0022","doi-asserted-by":"publisher","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"2025030422480139500_CIT0023","doi-asserted-by":"publisher","first-page":"113536","DOI":"10.1016\/j.ejca.2024.113536","article-title":"Association of antibiotic treatment with survival outcomes in treatment-na\u00efve melanoma patients receiving immune checkpoint blockade","volume":"200","author":"Chorti","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025030422480139500_CIT0024","doi-asserted-by":"publisher","first-page":"101251","DOI":"10.1016\/j.xcrm.2023.101251","article-title":"Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response","volume":"4","author":"Kim","year":"2023","journal-title":"Cell Rep Med"},{"key":"2025030422480139500_CIT0025","doi-asserted-by":"publisher","first-page":"6160","DOI":"10.1158\/1078-0432.CCR-18-3603","article-title":"Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer","volume":"25","author":"Greally","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025030422480139500_CIT0026","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/14737140.2020.1781620","article-title":"Palliative care for advanced gastric cancer","volume":"20","author":"Harada","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025030422480139500_CIT0027","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1148\/radiol.2532082272","article-title":"Peritoneal metastasis: detection with 16- or 64-detector row CT in patients undergoing surgery for gastric cancer","volume":"253","author":"Kim","year":"2009","journal-title":"Radiology"},{"key":"2025030422480139500_CIT0028","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.crad.2012.07.015","article-title":"The role of CT and staging laparoscopy in the staging of gastric cancer","volume":"68","author":"Burbidge","year":"2013","journal-title":"Clin Radiol"},{"key":"2025030422480139500_CIT0029","doi-asserted-by":"publisher","first-page":"1257638","DOI":"10.3389\/fcimb.2023.1257638","article-title":"The impact of concurrent bacterial lung infection on immunotherapy in patients with non-small cell lung cancer: a retrospective cohort study","volume":"13","author":"Cao","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"2025030422480139500_CIT0030","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1016\/j.cell.2021.04.016","article-title":"Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis","volume":"184","author":"Cui","year":"2021","journal-title":"Cell"},{"key":"2025030422480139500_CIT0031","doi-asserted-by":"publisher","first-page":"eaao4227","DOI":"10.1126\/science.aao4227","article-title":"Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice","volume":"361","author":"Albrengues","year":"2018","journal-title":"Science"},{"key":"2025030422480139500_CIT0032","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","article-title":"Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab","volume":"6","author":"Capone","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"2025030422480139500_CIT0033","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3892\/ol.2023.13905","article-title":"Pretreatment high cholesterol and low neutrophils predict complete pathological response after neoadjuvant short-course radiotherapy followed by chemotherapy and immunotherapy in locally advanced rectal cancer","volume":"26","author":"Zhang","year":"2023","journal-title":"Oncol Lett"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/2\/oyae362\/62202757\/oyae362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/2\/oyae362\/62202757\/oyae362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T22:48:21Z","timestamp":1741128501000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae362\/8045858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae362","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2]]},"article-number":"oyae362"}}